The FDA announced it is investigating the Zecuity (sumatriptan iontophoretic transdermal system, Teva) patch for migraine headache, regarding a risk for serious burns and potential permanent scarring.
“Since marketing of the Zecuity patch began in September 2015, a large number of patients have reported they experienced burns or scars on the skin where the patch was worn,” according to the agency. “The FDA is investigating these serious adverse events to determine whether